Physician profile

Mary Grant

Chattanooga, TN

NPI 1477313658

$770.97

in general payments reported to CMS, 2019-2025

7 companies · $618 in 2025

The $618 reported for 2025 was more than what 82% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$770.97

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sage Therapeutics, LLC $405.78 2024-2025 Zurzuvae
Mayne Pharma Commercial LLC $157.24 2025
Sumitomo Pharma America, INC. $63.90 2024-2025 Myfembree
Supernus Pharmaceuticals, INC. $41.51 2025 Qelbree
Pfizer INC. $40.74 2024
Astellas Pharma US INC $34.32 2025 Veozah
Novo Nordisk INC $27.48 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mary Grant

$770.97

in general payments reported 2019-2025

Years
2024-2025
Top company
Sage Therapeutics, LLC
Context
The $618 reported for 2025 was more than what 82% of providers received nationally.

https://glasscript.com/doctor/11683816/mary-grant

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.